Not available
Quote | argenx SE (NASDAQ:ARGX)
Last: | $375 |
---|---|
Change Percent: | -1.54% |
Open: | $380.85 |
Close: | $375 |
High: | $380.85 |
Low: | $372.68 |
Volume: | 202,220 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | argenx SE (NASDAQ:ARGX)
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Message Board Posts | argenx SE (NASDAQ:ARGX)
Subject | By | Source | When |
---|---|---|---|
Looking good | Fred Kadiddlehopper | investorshub | 02/24/2021 2:20:34 PM |
Progress in Sub-cu Efgartigimod was discussed in some | Fred Kadiddlehopper | investorshub | 02/24/2021 2:19:32 PM |
3 Penny Stocks To Buy Or Sell Before | jonny_red | investorshub | 11/05/2019 8:13:01 PM |
* * $AGRX Video Chart 11-01-18 * * | ClayTrader | investorshub | 11/01/2018 9:46:41 PM |
Efgartigimod is a first-in-class antibody fragment designed for | riche | investorshub | 10/17/2018 8:09:07 AM |
News, Short Squeeze, Breakout and More Instantly...
argenx SE Company Name:
ARGX Stock Symbol:
NASDAQ Market:
2024-04-18 12:15:04 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for ARGX on April 18, 2024 10:01AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $363.76 at issue of the analyst recommendation. The overall analyst consensu...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patien...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...